Cardiff Oncology Inc. (XE7C)
XMUN 
Summary
XE7C Chart
Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer
Cardiff Oncology posted Phase II data for onvansertib in RAS-mutated mCRC, showing a 72% ORR versus 40–45% for standard-of-care. Onvansertib's efficacy, durability, and safety profile suggest it could become a first-line standard-of-care backbone in a $1.2B–$2.5B U.S. market. Despite positive data, CRDF trades near $1.50/share due to small sample size, data immaturity, and anticipated dilution; risk remains high.
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
Cardiff Oncology Inc. (XE7C) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cardiff Oncology Inc. ever had a stock split?
Cardiff Oncology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mani Mohindru CEO | XMUN Exchange | US14147L1089 ISIN |
| US Country | 31 Employees | - Last Dividend | 20 Feb 2019 Last Split | - IPO Date |
Overview
Cardiff Oncology, Inc. is a clinical-stage biotechnology company that is dedicated to developing novel therapies designed to combat various forms of cancer. With its headquarters located in San Diego, California, the company has carved out a niche in the oncology field through its focus on leveraging advanced scientific research to create effective treatments. Founded in 1999, Cardiff Oncology initially bore the name Trovagene, Inc. before rebranding to its current identity in May 2012. This rebranding signifies the company's evolution and focused commitment towards oncology. As a player in the biotechnology industry, Cardiff Oncology serves primarily pharmaceutical manufacturers by providing innovative drug candidates for cancer treatment.
Products and Services
- Onvansertib:
- TROV-054 (Phase 1b/2):
An oral selective Polo-like Kinase 1 Inhibitor, onvansertib is Cardiff Oncology’s lead drug candidate. It is in active development for the treatment of a broad spectrum of solid tumor cancers. Additionally, onvansertib is being evaluated for its efficacy against specific mutations—KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic cancer. Beyond these focus areas, investigator-initiated trials are exploring onvansertib’s potential applications in managing triple-negative breast cancer and small cell lung cancer. This diversification of application envisions onvansertib as a cornerstone in precision oncology.
This drug candidate represents Cardiff Oncology’s foray into more targeted therapy combinations. TROV-054 is currently in Phase 1b/2 clinical trials, being evaluated in combination with FOLFIRI and bevacizumab. The aim here is to determine the efficacy and safety of such a combination therapy in patients, thereby expanding the potential treatment options available for oncologists and their patients. It signifies Cardiff Oncology’s commitment to developing comprehensive treatment strategies that address the complexity and heterogeneity of cancer.
